Prehypertension: Progression to hypertension and management considerations

Current Cardiovascular Risk Reports

Volumn 1, Issue 3, 2007, Pages 188-197

  Persell, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873512810     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-007-0031-7     Document Type: Article

References (55)

1. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289: 2560-2572.
2. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157: 2413-2446.
3. Vasan RS, Beiser A, Seshadri S, et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002, 287: 1003-1010.
4. Greenlund KJ, Croft JB, Mensah GA: Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med 2004, 164: 2113-2118.
5. Vasan RS, Larson MG, Leip EP, et al.: Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001, 358: 1682-1686.
6. Winegarden CR: From "prehypertension" to hypertension? Additional evidence. Ann Epidemio 2005, 15: 720-725.
7. Julius S, Nesbitt SD, Egan BM, et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354: 1685-1697.
8. Kannel WB, Brand N, Skinner JJ Jr, et al.: The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med 1967, 67: 48-59.
9. Moore LL, Visioni AJ, Qureshi MM, et al.: Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. Arch Intern Med 2005, 165: 1298-1303.
10. Halperin RO, Sesso HD, Ma J, et al.: Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006, 47: 45-50.
11. Haffner SM, Miettinen H, Gaskill SP, Stern MP: Metabolic precursors of hypertension. The San Antonio Heart Study. Arch Intern Med 1996, 156: 1994-2001.
12. Glorioso N, Troffa C, Filigheddu F, et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34: 1281-1286.
13. Ferrier KE, Muhlmann MH, Baguet JP, et al.: Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002, 39: 1020-1025.
14. Port S, Demer L, Jennrich R, et al.: Systolic blood pressure and mortality. Lancet 2000, 355: 175-180.
15. Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360: 1903-1913.
16. Kannel WB, Vasan RS, Levy D: Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values?Hypertension 2003, 42: 453-456.
17. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al.: The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000, 342: 1-8.
18. Vasan RS, Larson MG, Leip EP, et al.: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345: 1291-1297.
19. Liszka HA, Mainous AG 3rd, King DE, et al.: Prehypertension and cardiovascular morbidity. Ann Fam Med 2005, 3: 294-299.
20. Mainous AG 3rd, Everett CJ, Liszka H, et al.: Prehypertension and mortality in a nationally representative cohort. Am J Cardiol 2004, 94: 1496-1500.
21. Zhang Y, Lee ET, Devereux RB, et al.: Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 2006, 47: 410-414.
22. Kshirsagar AV, Carpenter M, Bang H, et al.: Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006, 119: 133-141.
23. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342: 145-153.
24. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362: 782-788.
25. Braunwald E, Domanski MJ, Fowler SE, et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351: 2058-2068.
26. Poole-Wilson PA, Lubsen J, Kirwan BA, et al.: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004, 364: 849-857.
27. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005, 23: 641-648.
28. Nissen SE, Tuzcu EM, Libby P, et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004, 292: 2217-2225.
29. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358: 1033-1041.
30. PROGRESS Collaborative Group: Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003, 24: 475-484.
31. Neaton JD, Grimm RH Jr, Prineas RJ, et al.: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993, 270: 713-724.
32. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363: 2022-2031.
33. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288: 2981-2997.
34. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290: 2805-2816.
35. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000, 283: 1967-1975.
36. Messerli FH, Mancia G, Conti CR, et al.: Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?Ann Intern Med 2006, 144: 884-893.
37. Farnett L, Mulrow CD, Linn WD, et al.: The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991, 265: 489-495.
38. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351: 1755-1762.
39. Weber T, Auer J, Eber B, O'Rourke MF: Diastolic blood pressure in coronary artery disease. Ann Intern Med 2007, 146: 149.
40. Stamler R, Stamler J, Gosch FC, et al.: Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized, controlled trial. JAMA 1989, 262: 1801-1807.
41. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997, 157: 657-667.
42. Whelton PK, Appel LJ, Espeland MA, et al.: Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998, 279: 839-846.
43. Appel LJ, Moore TJ, Obarzanek E, et al.: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997, 336: 1117-1124.
44. Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344: 3-10.
45. Vollmer WM, Sacks FM, Ard J, et al.: Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001, 135: 1019-1028.
46. Appel LJ, Champagne CM, Harsha DW, et al.: Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003, 289: 2083-2093.
47. Whelton SP, Chin A, Xin X, He J: Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136: 493-503.
48. Cornelissen VA, Fagard RH: Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension 2005, 46: 667-675.
49. Cornelissen VA, Fagard RH: Effect of resistance training on resting blood pressure: a meta-analysis of randomized controlled trials. J Hypertens 2005, 23: 251-259.
50. Stamler R, Stamler J, Grimm R, et al.: Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial-the Hypertension Control Program. JAMA 1987, 257: 1484-1491.
51. Persell SD, Baker DW: Studying Interventions to Prevent the Progression from Prehypertension to Hypertension: Does TROPHY Win the Prize?Am J Hypertens 2006, 19: 1095-1097.
52. Meltzer JI: A specialist in clinical hypertension critiques the TROPHY trial. Am J Hypertens 2006, 19: 1098-1100.
53. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21: 1011-1053.
54. Bosch J, Yusuf S, Pogue J, et al.: Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002, 324: 699-702.
55. Svensson P, de Faire U, Sleight P, et al.: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001, 38: E28-E32.